The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy

The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy

Ovarian cancer (OC) has a high impact on morbidity and mortality in the female population. Survival is modest after platinum progression. Therefore, the search for new therapeutic strategies is of utmost importance. <i>BRCA</i> mutations and HR-deficiency occur in around 50% of OC, leadi...

Full description

Bibliographic Details
Main Authors: Brigida Anna Maiorano, Domenica Lorusso, Mauro Francesco Pio Maiorano, Davide Ciardiello, Paola Parrella, Antonio Petracca, Gennaro Cormio, Evaristo Maiello
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:International Journal of Molecular Sciences
Subjects:
<i>BRCA</i>
PARP inhibitors
HRD
immune checkpoint inhibitors
ICIs
ovarian cancer
Online Access:https://www.mdpi.com/1422-0067/23/7/3871

Internet

https://www.mdpi.com/1422-0067/23/7/3871

Similar Items